share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K:外國發行人報告(業績相關)
美股SEC公告 ·  2024/11/01 05:01

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) on October 31, 2024, securing access to up to $30 million in equity financing. The agreement grants the company the right to sell ordinary shares to Yorkville over a 36-month period at a 3% discount to the lowest three-day VWAP.The company will issue 224,697 ordinary shares to Yorkville as commitment shares and pay a $25,000 structuring fee. The purchase agreement includes restrictions limiting Yorkville's beneficial ownership to 4.99% of outstanding voting shares. The financing arrangement is subject to SEC registration requirements and customary closing conditions.Implementation of the agreement requires filing and SEC approval of a registration statement covering both commitment shares and future advance shares. The shares are being offered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with Yorkville representing as an accredited investor purchasing for investment purposes.
NeuroSense Therapeutics has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) on October 31, 2024, securing access to up to $30 million in equity financing. The agreement grants the company the right to sell ordinary shares to Yorkville over a 36-month period at a 3% discount to the lowest three-day VWAP.The company will issue 224,697 ordinary shares to Yorkville as commitment shares and pay a $25,000 structuring fee. The purchase agreement includes restrictions limiting Yorkville's beneficial ownership to 4.99% of outstanding voting shares. The financing arrangement is subject to SEC registration requirements and customary closing conditions.Implementation of the agreement requires filing and SEC approval of a registration statement covering both commitment shares and future advance shares. The shares are being offered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with Yorkville representing as an accredited investor purchasing for investment purposes.
NeuroSense Therapeutics 於2024年10月31日與 YA II PN, LTD. (Yorkville) 簽署了一份備用股權購買協議,確保獲得高達3000萬美元的股權融資。該協議賦予公司在36個月內以最低三日VWAP的3%折扣向Yorkville出售普通股的權利。公司將向Yorkville發行224,697股普通股作爲承諾股,並支付25000美元的結構費用。購買協議包括限制條款,限制Yorkville的有利所有權不超過4.99%的未償還投票股。該融資安排鬚遵循SEC註冊要求和慣例成交條件。實施該協議需要提交併獲得SEC對包括承諾股和未來預付款股的註冊聲明的批准。這些股份在證券法第4(a)(2)節和監管D第506條下發售,Yorkville作爲合格投資者,代表其購買用於投資目的。
NeuroSense Therapeutics 於2024年10月31日與 YA II PN, LTD. (Yorkville) 簽署了一份備用股權購買協議,確保獲得高達3000萬美元的股權融資。該協議賦予公司在36個月內以最低三日VWAP的3%折扣向Yorkville出售普通股的權利。公司將向Yorkville發行224,697股普通股作爲承諾股,並支付25000美元的結構費用。購買協議包括限制條款,限制Yorkville的有利所有權不超過4.99%的未償還投票股。該融資安排鬚遵循SEC註冊要求和慣例成交條件。實施該協議需要提交併獲得SEC對包括承諾股和未來預付款股的註冊聲明的批准。這些股份在證券法第4(a)(2)節和監管D第506條下發售,Yorkville作爲合格投資者,代表其購買用於投資目的。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息